An2 Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: AN2 Therapeutics Reports 2024 Results, Navigates Pipeline Strategy After Phase 2/3 Trial Update
AN2 Therapeutics focuses on its boron chemistry platform and pipeline programs for Chagas disease, NTM, melioidosis, and oncology after topline results from the Phase 2 part of the EBO-301 study.
NASDAQ
AN2 Therapeutics has filed an amendment to its annual report to include previously omitted certification language regarding internal controls over financial reporting.
NASDAQ
AN2 Therapeutics' annual 10-K filing details a pause in their Phase 3 clinical trial for epetraborole, along with updates on other pipeline programs and financial status.